Working… Menu

Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02514239
Recruitment Status : Completed
First Posted : August 3, 2015
Last Update Posted : July 9, 2020
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
The primary objective of this trial is to determine the maximum tolerated dose (MTD) of BI 836909 administered by continuous i.v. infusion in patients with relapsed and/or refractory multiple myeloma. If the MTD is not reached based on safety findings, a recommended dose for further development will be determined. This will depend on the safety data, pharmacokinetic/pharmacodynamics data and potentially preliminary efficacy data. Secondary objectives are to document the safety and tolerability of BI 836909, to perform pharmacokinetic and pharmacodynamic analyses and to evaluate relevant biological effects in terms of parameters of efficacy.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: BI 836909 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 43 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Phase I, Dose Escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Doses of BI 836909 in Relapsed and/or Refractory Multiple Myeloma Patients
Actual Study Start Date : July 8, 2015
Actual Primary Completion Date : July 17, 2018
Actual Study Completion Date : July 2, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: BI 836909
given as continuous intravenous infusion
Drug: BI 836909

Primary Outcome Measures :
  1. Number of patients with dose limiting toxicities (DLTs) [ Time Frame: 2 - 4 weeks after start of treatment ]
  2. Maximum tolerated dose (MTD) of BI 836909 [ Time Frame: 2 - 4 weeks after start of treatment ]

Secondary Outcome Measures :
  1. Objective response rate (percentage of patients with response) [ Time Frame: 30 months ]
  2. Duration of response [ Time Frame: 30 months ]
  3. Minimal residual disease (MRD) response rate [ Time Frame: 30 months ]
  4. Progression free survival [ Time Frame: 30 months ]
  5. Maximum concentration of BI 836909 at steady state [ Time Frame: 28 weeks ]
  6. Duration of MRD response [ Time Frame: 30 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Patients with a documented diagnosis of relapsed and/or refractory multiple myeloma who progressed after at least two prior treatment regimens, including both proteasome inhibitor as well as an immune-modulatory drug at time of screening
  • must have measurable disease, defined by one or more of following at time of screening:

    • a serum M protein > 0.5 g/dl measured by serum protein electrophoresis
    • urinary M protein excretion > 200 mg/24 hours
    • serum free light chain (FLC) measurement > 10 mg/dl, provided that the serum FLC ratio is abnormal
  • Relapse or progression of disease with an indication for therapy as per investigator´s judgement at time of screening
  • ECOG Performance Status 0, 1 or 2 at time of screening
  • Age >= 18 years at time of screening
  • Written informed consent which is consistent with ICH_GCP guidelines and local legislation
  • Able to adhere to the study visit schedule e.g. ability to come to the clinic and to other protocol requirements
  • Indwelling central venous cateder or willingness to undergo intra venous central line placement.

Exclusion criteria:

  • Plasma cell leukemia
  • Extramedullary relapse of multiple myeloma
  • Known central nervous system involvement by multiple myeloma
  • Last anticancer treatment < 2 weeks prior to visit 1
  • Last treatment with a therapeutic antibody less than 6 weeks prior to visit 1
  • Prior allogeneic stem cell transplantation or solid organ transplantation
  • Autologous bone marrow transplantation < than 90 days at time of treatment start
  • Last corticosteroid < 2 weeks prior to visit 1 unless the dose is <= 10 mg/day prednisolone or equivalent
  • AST or ALT > 3 x upper limit of normal (CTCAE version 4.03 grade 2 or higher) at time of screening
  • Total conjugated bilirubin > 1.5 x upper limit of normal (CTCAE version 4.03 grade 2 or higher) at time of screening
  • Absolute neutrophil count < 1.0 x 109/L (without growth factor support) at time of screening
  • Platelets < 25 x 109/L (without transfusions) at time of screening
  • Calculated GFR < 30 mL/min (Cockcroft-Gault Formula) at time of screening
  • Clinical relevant concurrent medical disease or condition which according to the investigator's judgement would either compromise patient safety or interfere with the evaluation of the safety of the test drug, e.g. symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia requiring therapy at time of screening
  • clinically not controlled chronic or ongoing infectious disease requiring treatment at the time of enrolment or within the previous two weeks
  • Active hepatitis B or C, or laboratory evidence for a chronic infection with hepatitis B or C at time of screening; HIV infection at time of screening
  • Women of childbearing potential not using highly effective method of birth control during the trial until one year after the last dose. Highly effective methods of birth control are defined as those which result in a low failure rate (i.e. less than 1% per year)when used consistently and correctly used such as implants, injectables, combined oral contraceptives, intrauterine devises (IUDs), sexual abstinence or vasectomised partner. Barrier methods of contraception are accepted if condom or occlusive cap is used together with spermicides (e.g. foam, gel). Female patients will be considered to be of childbearing potential unless surgically sterilized by hysterectomy or bilateral tubal ligation/salpingectomy, or postmenopausal (12 months with no menses without an alternative medical cause
  • Male patients with partners of childbearing potential who are unwilling to use condoms in combination with a second medically acceptable method of contraception during the trial and for a minimum of 6 months after treatment
  • Pregnancy or breast feeding
  • Known or suspected active alcohol or drug abuse as per investigator's judgement
  • Treatment with another investigational drug within the past four weeks before start of therapy or concomitantly with this trial
  • Patients with known hypersensitivity to any comonent of the study drug
  • Patients with other malignancies within 5 years at time of screening (except basal cell or squamous cell carcinoma of the skin or carcinoma in situ treated with curative therapy)
  • Known autoimmune diseases requiring systemic treatment in past 5 years and interfering with evaluation of study drug
  • Pre-existing disorders of the central nervous system

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02514239

Layout table for location information
HOP Claude Huriez
Lille, France, 59037
HOP Hôtel-Dieu
Nantes, France, 44000
INS Universitaire du Cancer
Toulouse, France, 31059
Universitätsklinikum Ulm
Ulm, Germany, 89081
Universitätsklinikum Würzburg
Würzburg, Germany, 97080
Sponsors and Collaborators
Boehringer Ingelheim
Layout table for investigator information
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Boehringer Ingelheim Identifier: NCT02514239    
Other Study ID Numbers: 1351.1
2014-004896-22 ( EudraCT Number )
First Posted: August 3, 2015    Key Record Dates
Last Update Posted: July 9, 2020
Last Verified: July 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases